Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This clinical trial evaluated the comparative bioavailability of two injectable suspension
formulations of medroxyprogesterone acetate + estradiol cypionate, a test (Depomês®, 25 mg/mL
medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.)
and a reference formulation (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5
mg/0.5 mL estradiol cypionate, Millet Roux Ltda.) in healthy female volunteers after a single
intramuscular dose administration. In addition, this study also evaluated the safety and
tolerability of these drugs.